Review of pediatric teduglutide use for short bowel syndrome, synthesizing trials and real-world data to guide treatment timing and duration.
Key Takeaways
- This rate is much higher than the 16% reported in a 2022 systematic review of 14 pediatric studies
- Its clinical efficacy for SBS-IF has been confirmed in multiple clinical and real-world studies ( 8 )
- TED is the first GLP-2 analog developed and marketed for SBS-IF